Explore /
Poster
/ ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).

Authors

Louise Emmett

Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, NSW, Australia

Louise Emmett , Shalini Subramaniam , Alison Yan Zhang , Andrew James Martin , Sonia Yip , Megan Crumbaker , Nisha Rana , Kate Ford , Ailsa Langford , Roslyn J. Francis , Michael S Hofman , Anthony M. Joshua , Shahneen Kaur Sandhu , Arun Azad , Craig Gedye , Margaret Mary McJannett , Martin R. Stockler , Ian D. Davis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Advanced Prostate Cancer

Track

Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04419402

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr TPS177)

DOI

10.1200/JCO.2021.39.6_suppl.TPS177

Abstract #

TPS177

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Genitourinary Cancers Symposium